Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and MRI in Anxious Depression
NCT02544607Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ketamine in mixed anxiety and depressive disorder (MADD), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Hamilton Depression Rating Scale at 4 hours. Started Mar 2016; status: completed.
02
Drugs
ketamine
03
Conditions
mixed anxiety and depressive disorder (MADD)
Beyond the preview
Go deeper on NCT02544607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544607.